Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
Titel:
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
Auteur:
O'Brien, Susan Jones, Jeffrey A Coutre, Steven E Mato, Anthony R Hillmen, Peter Tam, Constantine Österborg, Anders Siddiqi, Tanya Thirman, Michael J Furman, Richard R Ilhan, Osman Keating, Michael J Call, Timothy G Brown, Jennifer R Stevens-Brogan, Michelle Li, Yunfeng Clow, Fong James, Danelle F Chu, Alvina D Hallek, Michael Stilgenbauer, Stephan